Tumor Infiltrating Lymphocytes

Phase 2Cell therapy

EEssen Biotech

Tumor Infiltrating Lymphocytes is one of 381 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

380

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Brain CancerActive, not recruiting

Intestinal CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

Uveal MelanomaActive, not recruiting

Brain GliomaActive, not recruiting

Biliary Tract CancerActive, not recruiting

Rectum CancerActive, not recruiting

Breast CancerActive, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Brain CancerPhase 1/Phase 2

Active, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Uveal MelanomaPhase 2

Active, not recruiting

Brain GliomaPhase 1

Active, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Rectum CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Tumor Infiltrating Lymphocytes

EEssen Biotech

Phase 2

3 4

Avastin

Voltaren

1 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Gastrointestinal Tumors

NCT04960072

Q4 2026

Phase 1/2Recruiting

Esophageal Cancer

NCT06532799

Phase 1/2Recruiting

Breast Cancer

NCT06532812

Phase 1/2Recruiting

Lung Cancer

NCT06538012

Phase 1/2Recruiting

Rectum Cancer

NCT06530303

Phase 1/2Recruiting

Brain Cancer

NCT06640582

Clinical

Trials by Indication[1]

Metastatic Melanoma5 trials

Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy

Unknown status·HHadassah Medical Organization·Phase 2·NCT00604136·20 enrolled

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01369875·2 enrolled

A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas

Terminated·SSaint John's Cancer Institute·Phase 2·NCT02375984·1 enrolled

Show 2 more trials

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Terminated·WWake Forest University Health Sciences·Phase 2·NCT00863330·14 enrolled

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01369888·3 enrolled

Breast Cancer3 trials

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Completed·YYale University·Phase 2·NCT04111510·6 enrolled

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06532812·85 enrolled

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

Recruiting·SShanghai Juncell Therapeutics·Phase 1·NCT05142475·50 enrolled

Advanced Solid Tumors3 trials

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

Recruiting·SShanghai Juncell Therapeutics·Phase 1·NCT05087745·50 enrolled

A Study of GC101 TIL in Advanced Solid Tumors (TR)

Recruiting·SShanghai Juncell Therapeutics·Phase 1·NCT04967833·20 enrolled

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Not yet recruiting·FFujian Cancer Hospital·Phase 1·NCT05649618·42 enrolled

Ovarian Cancer2 trials

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated·IInge Marie Svane·Phase 1/2·NCT04611126·6 enrolled

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer

Unknown status·LLeiden University Medical Center·Phase 1/2·NCT04072263·12 enrolled

Pilot Study1 trial

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Terminated·YYale University·Phase 1·NCT03526185·6 enrolled

15 more indications

Melanoma1 trial

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01883323·12 enrolled

Glioblastoma Multiforme1 trial

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT05333588·20 enrolled